Category: alopecia

  • Equillium triples clinical pipeline with $329m Bioniz takeover

    Equillium has announced another bolt-on deal to expand its pipeline tripling the size of its clinical pipeline to three drug candidates via a $329 million agreement to acquire Bioniz Therapeutics. The La Jolla, California-based biotech licensed its first drug – itolizumab for graft-versus-host disease (GvHD), asthma and lupus nephritis – from Indian drugmaker Biocon in […]

  • Lilly has a bad hair day as Pfizer rival hits the mark in alopecia

    Eli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer reported that its ritlecitinib improved scalp hair regrowth in a late-stage trial. In the phase 2b/3 ALLEGRO trial, JAK inhibitor ritlecitinib hit its primary objective of improving the area of scalp covered by hair in people with […]

  • Chasing Lilly, Concert eyes 2023 filing for its JAK drug for alopecia

    Concert Pharmaceuticals has started the second of two planned phase 3 trials of its drug candidate for alopecia areata (AA), a common cause of hair loss, and says it hopes to report results in the second half of 2022. The two studies – THRIVE-AA1 and THRIVE-AA2 – are testing oral JAK1/2 inhibitor CTP-543 in adults […]